Navigation Links
Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
Date:10/27/2009

logy's Head of Corporate Development and International Operations. "We were impressed by the potential of TAR-1 and we are planning to continue to in-license oncology drug candidates with compelling science and to develop only those with positive Tumorgraft results." TAR-1 will undergo Tumorgraft testing as Champions completes Tumorgraft testing of its other oncology drug, SG410, a tubulin inhibitor.

"We are excited to work with Champions Biotechnology. Their predictive platform and experienced scientific and clinical team make them an ideal candidate to move TAR-1 forward into the clinic and on the path to commercialization," said Dr. Ze'ev Weinfeld, CEO, Ramot at Tel Aviv University Ltd.

For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predic
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
5. Wound Management Technologies (OTCBB- WNDM) Signs Biotech Agreement With Biocure S.r.l. of Milan, Italy
6. NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer
7. Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement
8. Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in Peoples Republic of China
9. AccuVein Signs Multiple-Country Distribution Agreement in Europe for Vein Illumination Device
10. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
11. Paratek Pharmaceuticals Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2014. Cash ... $301.4 million as compared to $309.1 million at March 31, ... for Nektar as we look forward to significant milestones for ... Robin, President and Chief Executive Officer of Nektar. "The first ...
(Date:7/31/2014)...   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... announced that the Company will release results for the ... before the opening of the U.S. financial markets. The ... at 8:30 a.m. ET to discuss results and highlights ... to be used during the call will be available ...
(Date:7/31/2014)... SARASOTA, Fla. , July 31, 2014 ... announced today that it has initiated the development of ... ; and that it has selected Quotient Clinical, ... United Kingdom (UK) to run its early ... a Clinical Trial Application (CTA) by the end of ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
(Date:8/2/2014)... Dr. Ping Hu is a worldly ... in Medicine from the Capital Medical University in Beijing, ... Medical Microbiology from the University of London. She ... Sciences Center and finished her fellowship at the University ... was active both inside and outside of the classroom ...
(Date:8/2/2014)... August 02, 2014 When the Black Hat ... 2nd this year, one thing can be always counted on, ... known as fear, uncertainty and doubt. The run-up has ... this article published by Reuters on July 31st about ... mouse or keyboard to successfully infect a system with malware, ...
(Date:8/1/2014)... (PRWEB) August 02, 2014 The successful ... the stamping business of Guangdong FODAY Automobile Co.,LTD. As ... the company had already organized an excellent team to ... number of detailed, in-depth technical plans. The company’s vice ... were in the direct involvement of the specific arrangement ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Cannabis use among ... teens aged 14 to 17 having used marijuana at least ... With their slogan “Say ‘No’ to Drugs, Say ‘Yes to ... reaching out to youth this summer with factual information about ... past six months, Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ ...
(Date:8/1/2014)... Diego School of Medicine report that dietary capsaicin ... activation of a receptor on cells lining the intestines ... risk of colorectal tumors. , The findings are published ... Journal of Clinical Investigation . , The receptor or ... neurons, where it acts as a sentinel for heat, ...
Breaking Medicine News(10 mins):Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 3Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 4Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 5Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2
... Reporter , TUESDAY, May 3 (HealthDay News) -- A structured ... blood sugar level more effectively than just receiving advice about ... data. After analyzing the results of 47 randomized ... periods of time was better at bringing blood sugar levels ...
... , TUESDAY, May 3 (HealthDay News) -- ... women, a new study shows. Duke University researchers ... completed a sexual functioning questionnaire before enrolling in a ... desire, arousal, orgasm, satisfaction, behavior, relationship, masturbation and sexual ...
... produces feelings of euphoria and emotional warmth has ... Clinical trials are testing Ecstasy in the treatment of ... magazine,s health section in February "Ecstasy as therapy: ... concern Ronald Cowan, M.D., Ph.D., associate professor of Psychiatry. ...
... (HealthDay News) -- Americans are feeling the pain of ... Mississippi has found a potential silver lining: Traffic ... of drunken driving -- as gas prices go ... short-term and intermediate-term effects on reducing traffic crashes," Guangqing ...
... and Boston Medical Center have found that by adding one ... hospital readmission costs by $579 million per year, or 83 ... target. These findings currently appear on the website of the ... of family physicians has fallen over the last decade due ...
... This release is available in Spanish . ... shelf to find the freshest salad greens with the latest ... Agriculture (USDA) scientists may prompt consumers to instead look for ... closest to the front. The study was led by ...
Cached Medicine News:Health News:Structured Exercise Programs Help Lower Blood Sugar, Study Finds 2Health News:Structured Exercise Programs Help Lower Blood Sugar, Study Finds 3Health News:Obese People Have Less Satisfying Sex Lives: Study 2Health News:Ecstasy associated with chronic change in brain function 2Health News:Researchers find increasing the number of family physicians reduces hospital readmissions 2Health News:Market lighting affects nutrients 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: